Drug Type Oligonucleotide |
Synonyms- |
Action inhibitors |
Mechanism CGAS inhibitors(cyclic GMP-AMP synthase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Cardiovascular Diseases | Discovery | - | 10 Nov 2023 | |
| Congenital Disorders | Discovery | - | 10 Nov 2023 | |
| Digestive System Disorders | Discovery | - | 10 Nov 2023 | |
| Endocrinology and Metabolic Disease | Discovery | - | 10 Nov 2023 | |
| Eye Diseases | Discovery | - | 10 Nov 2023 | |
| Immune System Diseases | Discovery | - | 10 Nov 2023 | |
| Infectious Diseases | Discovery | - | 10 Nov 2023 | |
| Neoplasms | Discovery | - | 10 Nov 2023 | |
| Nervous System Diseases | Discovery | - | 10 Nov 2023 | |
| Other Diseases | Discovery | - | 10 Nov 2023 |





